ZLAB News and Press, Zai Lab Limited From 05/15/22

The following slide deck was published by Zai Lab Limited in conjunction with their 2022 Q1 earnings call. For further details see: Zai Lab Limited 2022 Q1 - Results - Earnings Call Presentation

Start Time: 08:00 End Time: 08:48 Zai Lab Limited (ZLAB) Q1 2022 Earnings Conference Call May 11, 2022, 08:00 AM ET Company Participants Samantha Du - Founder, Chairperson and CEO Billy Cho - CFO Alan Sandler - President, Head of Global Development, Oncology Harald Reinhart - President, Head ...

U.S.-listed shares of Zai Lab (NASDAQ:ZLAB) have added 8.2% to $28.38 in Wednesday morning trade, after the Chinese biotech's Q1 2022 earnings beat estimates. ZLAB posted Q1 GAAP EPS of -$0.09 which beat estimates by $1.05, and revenue of $46.72M which beat by $1M. The com...

Gainers: Blue Water Vaccines (BWV) +18%. Oscar Health (OSCR) +13%. Veru (VERU) +10%. Zai Lab (ZLAB) +8%. Better Therapeutics (BTTX) +6%. Losers: Inovio Pharmaceuticals (INO) -32%. iTeos Therapeutics (ITOS) -32%. Arcus Biosciences (RCUS) -28%. Akand...

Zai Lab press release (NASDAQ:ZLAB): Q1 GAAP EPS of -$0.09 beats by $1.05. Revenue of $46.72M (+132.4% Y/Y) beats by $1M. For further details see: Zai Lab GAAP EPS of -$0.09 beats by $1.05, revenue of $46.72M beats by $1M

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the first quarter of 2022, along with recent...

- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease severity - Statistically significant separation f...

Chinese President Xi Jinping directed that the government is committed to "deliver its economic growth target and support the healthy growth of internet platform companies." The edict from Xi himself is highly significant. He is committed to leveraging Alibaba and its peers to help me...

Chinese biotech Zai Lab (NASDAQ:ZLAB) and California-based precision oncology company, Turning Point Therapeutics (NASDAQ:TPTX) are trading lower on Thursday after reporting topline data from China for its lung cancer candidate, repotrectinib, from a Phase 1/2 trial. The TRIDENT-1 is a global...

91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ months with median ...